Recent Updates
Recently added Catalysts
CRDL Neutral Sentiment Score: 55/100

Borden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3 T 416.367.6000 F 416.367.6749 blg.com

Key Takeaway: Borden Ladner Gervais LLP has provided consent for the reference of their name in various sections of a prospectus supplement related to Cardiol Therapeutics Inc.'s Class A common shares issuance. The consent pertains to the regulatory filing dated October 8, 2024, under the U.S. Registration Statement Form F-10. The firm specified that this consent does not constitute an admission of being among the persons requiring such consent under the Securities Act of 1933.

Market Sentiment Analysis

Full Press Release Details

Borden Ladner Gervais LLP Bay Adelaide Centre, East Tower 22 Adelaide Street West Toronto, ON, Canada M5H 4E3
T 416.367.6000
F 416.367.6749
blg.com
Consent of Borden Ladner Gervais LLP
We hereby consent to the reference to our name
on the face page and under the headings "Documents Filed as Part of the U.S. Registration Statement" and "Legal
Matters," and to the reference to our name and use of our opinions under the headings "Eligibility for Investment"
and "Certain Canadian Federal Income Tax Considerations," in the prospectus supplement dated October 8,
2024 relating to the issuance by Cardiol Therapeutics Inc. of Class A common shares, which forms part of the Registration Statement on
Form F-10 (File No. 333- 280713).
In giving this consent, we do not admit that we
are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.
/s/ Borden Ladner Gervais LLP
Borden Ladner Gervais LLP

Frequently Asked Questions

What is the address of Borden Ladner Gervais LLP?

Borden Ladner Gervais LLP is located at 22 Adelaide Street West, Toronto, ON, Canada M5H 4E3.

What type of consent did Borden Ladner Gervais provide?

The firm consented to the use of its name in the Cardiol Therapeutics prospectus supplement.

When was the prospectus supplement dated?

The prospectus supplement is dated October 8, 2024.

For what purpose is Cardiol Therapeutics issuing shares?

Cardiol Therapeutics is issuing Class A common shares as part of its Registration Statement.

Does Borden Ladner Gervais admit to needing consent under the Securities Act?

No, they do not admit that they are in the category requiring consent under the Securities Act.

Last updated: Oct 8, 2024